WuXi AppTec

WuXi AppTec is a multinational pharmaceutical, biopharmaceutical, and medical device manufacturer. Small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics are the company's five core operations.

WuXi AppTec, as a global firm with facilities in Asia, Europe, and North America, offers a diverse range of R&D and manufacturing services to the pharmaceutical and healthcare industries worldwide, enabling them to accelerate discoveries and deliver revolutionary medicines to patients. WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing, and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development, and Manufacturing Organization), assisting customers in increasing the productivity of advancing healthcare products through cost-effective and efficient solutions.

In 2022, WuXi AppTec achieved an AA ESG rating from MSCI, and its open-access platform is enabling over 6,000 clients from over 30 countries to enhance the health of those in need - and to realize the ambition that "every drug can be made and every disease can be treated."

Founded: 2000
Headquarters: Shanghai, China

Key people: Dr. Ge Li

Website: https://www.wuxiapptec.com